Idiopathic pulmonary fibrosis trials in Germany

In Germany 21 Also abroad 111

21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Where
Bonn, Coswig, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg, Hemer, Leipzig, Luebeck, Marburg, Munich, Stuttgart, Wuppertal
Age
18 years and over
People
139 worldwide
Run by
AstraZeneca AB
See details and how to join2025-525016-41-00 · EU 2025-525016-41-00
Phase 2Taking people
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Where
Bamberg, Coswig, Essen, Frankfurt am Main, Giessen, Loewenstein, München, Rosenheim
Age
40 years and over
People
324 worldwide
Run by
Contineum Therapeutics
See details and how to joinNCT07284459 · EU 2025-521901-42-00
Phase 2Not yet taking people in Germany
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
Where
Aachen, Berlin, Donaustauf, Solingen, Stralstund
Age
40 years and over
People
70 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07926321 · EU 2026-527098-13-00
Phase 2Taking people
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Where
Berlin, Frankfurt, Hanover
Age
18 years and over
People
340 worldwide
Run by
Avalyn Pharma Inc.
See details and how to joinNCT06951217
Phase 2Not yet taking people in Germany
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
Where
Solingen
Age
18 years and over
People
112 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-526404-71-00 · EU 2026-526404-71-00
Phase 2Taking people
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Where
Essen, Giessen, Hamburg, Heidelberg
Age
40 years and over
People
120 worldwide
Run by
Rein Therapeutics
See details and how to joinNCT06968845 · EU 2025-520715-13-00
Phase 3Not yet taking people in Germany
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Where
Berlin, Coswig, Freiburg im Breisgau, Hamburg, Immenhausen, Mainz, Munich, Stralsund
Age
18 years and over
People
2,380 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00
Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Where
Bonn, Coswig, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg, Hemer, Konstanz, Leipzig, Lübeck, Marburg, Munich, Stuttgart, Witten, Wuppertal-Barmen
Age
40 years and over
People
359 worldwide
Run by
AstraZeneca
See details and how to joinNCT07652658
Phase 3Taking people
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Where
Bad Berka, Berlin, Hamburg, Hanover, Hemer, Solingen, Stralsund, Wuppertal
Age
40 years and over
People
1,100 worldwide
Run by
PureTech
See details and how to joinNCT07284602 · EU 2025-524493-42-00
Phase 3Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Where
Bad Berka, Coswig, Essen, Löwenstein, München, Rosenheim
Age
40 years and over
People
1,850 worldwide
Run by
United Therapeutics
See details and how to joinNCT04905693
Phase 2Taking people
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Where
Cologne, Essen, Frankfurt am Main, Giessen, Hamburg, Homburg, Kiel, Konstanz
Age
40 years and over
People
240 worldwide
Run by
Chiesi Farmaceutici S.p.A.
See details and how to joinNCT07516951 · EU 2024-514246-37-00
Phase 2Taking people
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent
Where
Berlin, Essen, Frankfurt am Main, Hanover, Munich
Age
18 years and over
People
128 worldwide
Run by
Avalyn Pharma Inc.
See details and how to join2024-518289-28-00 · EU 2024-518289-28-00
Phase 2Taking people
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Where
Frankfurt, Giessen, Heidelberg, Mainz, München, Stralsund
Age
40 years and over
People
160 worldwide
Run by
Avalyn Pharma Inc.
See details and how to joinNCT07194382 · EU 2025-523431-19-00
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Where
Berlin, Cologne, Coswig, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Immenhausen, Leipzig, Mainz, Marburg, Muennerstadt, Munich
Age
18 years and over
People
239 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2023-503697-21-01 · EU 2023-503697-21-01
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Where
Berlin, Cologne, Coswig, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Immenhausen, Konstanz, Leipzig, Mainz, Muennerstadt, Munich, Stralsund
Age
18 years and over
People
249 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2023-503699-25-00 · EU 2023-503699-25-00
Phase 2Not yet taking people in Germany
Study of safety and tolerability following administration of metformin in patients with idiopathic pulmonary fibrosis (IPF)
Where
Giessen, Heidelberg, Munich
Age
18 years and over
People
40
Run by
Philipps-Universitaet Marburg
See details and how to join2025-523341-10-00 · EU 2025-523341-10-00
Phase 2Taking people
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Where
Bad Berka, Donaustauf, Freiburg im Breisgau, Halle (Saale), Konstanz
Age
40 years and over
People
165 worldwide
Run by
AbbVie
See details and how to joinNCT07230288 · EU 2024-518013-25-00
No phaseTaking people
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Where
Coswig, Mainz, Munich
Age
18 years to 80 years
People
500 worldwide
Run by
University of Massachusetts, Worcester
See details and how to joinNCT06855329
Phase 2Not yet taking people in Germany
Investigation of breathable surfactant agent in patients with idiopathic lung fibrosis
Where
Giessen, Munich
Age
18 years and over
People
20
Run by
Philipps-Universitaet Marburg
See details and how to join2023-508544-22-00 · EU 2023-508544-22-00
Phase 3Taking people
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Where
Bad Berka, Coswig, Essen, Giessen, Hamburg, Hanover, Immenhausen, Loewenstein, Muennerstadt, Munich, Rosenheim
Age
18 years and over
People
698 worldwide
Run by
United Therapeutics
See details and how to joinNCT05943535 · EU 2023-504904-26-00
No phaseTaking people
Effects of Pulmonary Diseases and Their Treatment on Cardiac Function
Where
Aachen
Age
18 years to 99 years
People
120
Run by
Ayham Daher
See details and how to joinNCT05042219